rofecoxib has been researched along with Premature Rupture of Fetal Membranes in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rofecoxib has a significant but reversible effect on fetal renal function and the ductus arteriosus." | 2.71 | TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. ( Bennett, PR; Groom, KM; Jones, BA; Seed, P; Shennan, AH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Groom, KM | 1 |
| Shennan, AH | 1 |
| Jones, BA | 1 |
| Seed, P | 1 |
| Bennett, PR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia[NCT00442676] | Phase 2 | 0 participants (Actual) | Interventional | 2009-06-30 | Withdrawn (stopped due to No patients were recruited. Treatment drug expired.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for rofecoxib and Premature Rupture of Fetal Membranes
| Article | Year |
|---|---|
TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
Topics: Adult; Blood Flow Velocity; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus; Femal | 2005 |